You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,119,868


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,119,868
Title:Therapeutic methods
Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
Inventor(s): Walker; Jill (Research Triangle Park, NC), Voitenleitner; Christian (Research Triangle Park, NC)
Assignee: GlaxoSmithKline LLC (Wilmington, DE)
Application Number:14/239,184
Patent Claims:1. A method of treatment of Hepatitis C Virus (HCV) in a human in need thereof comprising administering to the human a compound of the structure: ##STR00051## or a pharmaceutically acceptable salt thereof, and a second therapeutic agent selected from the group consisting of: an HCV NS2 protease inhibitor, an HCV NS3/4A protease inhibitor, an HCV NS3 helicase inhibitor, an HCV NS4B replication factor inhibitor, an HCV NS5A replication factor inhibitor, an HCV NS5B polymerase inhibitor, an HCV entry inhibitor, an HCV internal ribosome entry site inhibitor, a microsomal triglyceride transfer protein inhibitor, an .alpha.-glucosidase inhibitor, a caspase inhibitor, a cyclophilin inhibitor, an immunomodulator, a metabolic pathway inhibitor, an interferon, and a nucleoside analogue.

2. The method according to claim 1, wherein the second therapeutic agent is an interferon.

3. The method according to claim 2, wherein the interferon is selected from the group consisting of interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, peginterferon alfa-2b, an interferon alfa-2b analogue, interferon alpha-2b XL, interferon alfacon-1, interferon alfa-n1, interferon omega, HDV-interferon, peginterferon beta, peginterferon lambda, and interferon-alpha5.

4. The method according to claim 3, wherein the interferon is selected from the group consisting of interferon alfa-2a, peginterferon alfa-2a, interferon alfa-2b, peginterferon alfa-2b, an interferon alfa-2b analogue, interferon alfacon-1, and interferon alfa-n1.

5. The method according to claim 2, further comprising administering a nucleoside analogue.

6. The method according to claim 5, wherein the nucleoside analogue is ribavirin.

7. The method according to claim 1, wherein the second therapeutic agent is selected from an HCV NS5A replication factor inhibitor or an HCV NS5B polymerase inhibitor.

8. The method according to claim 1, wherein the second therapeutic agent is Simeprevir.

9. The method according to claim 1, wherein the second therapeutic agent is PSI-7977 ("Sofosbuvir").

10. The method according to claim 1, wherein the second therapeutic agent is GS 5885 ("Ledipasvir").

11. A method of treatment of Hepatitis C Virus (HCV) in a human in need thereof comprising administering to the human a compound of the structure: ##STR00052## or a pharmaceutically acceptable salt thereof, in combination with an HCV NS5A replication factor inhibitor or an HCV NS5B polymerase inhibitor.

12. A method of treatment of Hepatitis C Virus (HCV) in a human in need thereof comprising administering to the human a compound of the structure: ##STR00053## or a pharmaceutically acceptable salt thereof, in combination with an HCV NS5A replication factor inhibitor and an HCV NS5B polymerase inhibitor.

Details for Patent 9,119,868

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2031-08-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2031-08-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2031-08-17
Hoffmann-la Roche Inc. ROFERON-A interferon alfa-2a For Injection 103145 06/04/1986 ⤷  Try a Trial 2031-08-17
Kadmon Pharmaceuticals Llc INFERGEN interferon alfacon-1 Injection 103663 10/06/1997 ⤷  Try a Trial 2031-08-17
Merck Sharp & Dohme Corp. PEGINTRON peginterferon alfa-2b Injection 103949 01/19/2001 ⤷  Try a Trial 2031-08-17
Merck Sharp & Dohme Corp. SYLATRON peginterferon alfa-2b For Injection 103949 03/29/2011 ⤷  Try a Trial 2031-08-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.